Supreme Court Blocks Purdue Pharma's $6B Sackler Opioid Settlement
$ABC
$CAH
$JNJ
$MCK
Other Pharmaceuticals
Health Care
Other Pharmaceuticals
Health Care
-Walll Street Journal
-Walll Street Journal
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 7/23/2025 | Hold → Buy | Erste Group | ||
| 6/6/2025 | $24.00 | Buy | Goldman | |
| 6/3/2025 | $179.00 | Equal Weight → Overweight | Wells Fargo | |
| 5/28/2025 | $25.00 | Buy | Truist | |
| 5/13/2025 | $153.00 | Outperform → Market Perform | Leerink Partners | |
| 5/12/2025 | $23.00 | Neutral → Overweight | Analyst | |
| 2/5/2025 | $140.00 → $150.00 | Hold → Buy | Jefferies | |
| 1/8/2025 | $130.00 → $144.00 | Hold → Buy | TD Cowen |
Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market.This approval and launch add to Teva's continued commitment to its complex generic medicine portfolio as part of its Pivot to Growth Strategy.Liraglutide injection is indicated for adults with obesity or overweight (excess weight) who also have weight related medical problems, and pediatric patients (12-17 years) with a weight greater than 60 kg and obesity to help them lose weight and keep the weight off. PARSIPPANY, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries
Yesterday Court Issued Final Injunction After Jury Finds that Biosense Webster's Unlawful, Anti-Competitive Practices Forced Hospitals to Purchase More Costly, Wasteful Products The Association of Medical Device Reprocessors (AMDR) announced that Judge James Selna of the U.S. District Court for the Central District of California has issued a permanent injunction against Johnson & Johnson's (NYSE: JNJ) Biosense Webster (BSW) medical device unit for unlawful, anti-competitive conduct. The ruling prohibits BSW from blocking hospitals' access to safe, lower-cost, FDA-regulated reprocessed cardiac catheters. The decision follows a jury verdict ordering BSW to pay plaintiff Innovative Health, L
DUBLIN, Ohio, Aug. 15, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on October 15, 2025 to shareholders of record at the close of business on October 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator o
For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin
For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not
For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
4 - MCKESSON CORP (0000927653) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
8-K - CARDINAL HEALTH INC (0000721371) (Filer)
N-PX - JOHNSON & JOHNSON (0000200406) (Filer)
144 - JOHNSON & JOHNSON (0000200406) (Subject)
SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)
SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)
SC 13G/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)
Erste Group upgraded Johnson & Johnson from Hold to Buy
Goldman initiated coverage of Teva Pharma with a rating of Buy and set a new price target of $24.00
Wells Fargo upgraded Cardinal Health from Equal Weight to Overweight and set a new price target of $179.00
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv
Johnson & Johnson (NYSE:JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610707025/en/ "We are thrilled to have Daniel join Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare inno
DUBLIN, Ohio, Aug. 15, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on October 15, 2025 to shareholders of record at the close of business on October 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator o
Fourth quarter revenue was relatively flat at $60.2 billion; revenue increased 21% excluding the impact of a previously communicated contract expirationFourth quarter GAAP1 operating earnings were $428 million and GAAP diluted EPS was $1.00Fourth quarter non-GAAP operating earnings increased 19% to $719 million and non-GAAP diluted EPS increased 13% to $2.08Fiscal Year 2025 adjusted free cash flow was $2.5 billionFiscal year 2026 non-GAAP EPS guidance2 raised to $9.30 to $9.50, from $9.10 to $9.30Company announces the acquisition of Solaris Health, the country's leading urology MSODUBLIN, Ohio, Aug. 12, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported fourth quarter fiscal year
McKesson Corporation (NYSE:MCK) has released its fiscal 2026 first quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, August 6 at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at inv